Patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) had fewer major CV events when given the GLP-1* receptor agonist albiglutide compared with placebo, adding to the CV benefit profile of GLP-1 receptor agonists, according to results of the Harmony Outcomes** trial presented at EASD 2018.
Hybrid closed-loop insulin therapy in patients with suboptimally controlled type 1 diabetes (T1D) helps to keep their sugar levels within range, a 12-week multicentre, multinational trial has shown, supporting the utility of closed-loop technology in clinical practice.
The GLP-1* receptor agonist lixisenatide may slow the progression of micro- and macroalbuminuria in patients with type 2 diabetes (T2D) and acute coronary syndrome, based on an exploratory analysis of the ELIXA** trial presented at EASD 2018.
Treatment with twincretin, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonist combined into a single drug (LY3298176), not only reduced blood glucose in patients with type 2 diabetes (T2D) – it came with an added benefit of weight loss, with no increase in hypoglycaemia in a phase IIb trial.
Treatment with the DPP-4* inhibitor linagliptin in addition to the standard of care has no impact on heart failure, cardiovascular (CV), or renal events compared with standard of care alone in patients with type 2 diabetes (T2D) who had a very high risk of CV events and/or kidney disease progression, according to the CARMELINA** postmarketing outcomes study, thus providing reassurance on the CV safety of at least one member of the drug class.
Long-term therapy with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) may improve glycaemic control and reverse disease progression, as well as induce significant weight loss, according to a study presented at EASD 2018.
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.